Dr. Shlomo Sadoun is the Co-Founder and CEO of SK-Pharma Group, a global pharmaceutical company that manufactures, sells, and markets generic, specialty pharma, hybrid generics, and biosimilar pharmaceutical products in over 18 countries. Additionally, Shlomo holds over 18 years of experience in the pharmaceutical industry, harnessing technological advancement towards the enhancement of cross-organizational business initiatives. Shlomo has developed a global strategic alliance with over 300 leading companies that share the same innovative and technology-driven mindset. SK-Pharma has launched over 300 products worldwide, the majority of which were first-to-market, value-added medicines and branded products. Shlomo’s capabilities to leverage technological features, including generative AI, in a fast and applicable manner has led his organization to be the fastest-growing pharmaceutical company in Israel and beyond. Shlomo attained a master’s degree in Global Management from Salford University in the UK and a Doctoral degree in Business Administration, with a specialization in public health, from the Royal Academy of Economics and Technology in Switzerland additionally, Shlomo has completed over 21 academic courses in leading Universities as Harvard, NYU, University of Southern California, Osaka University and more. Additionally, Shlomo had been chosen as one of the 10 most innovative CEOs to follow in 2024 by CIOVIEWS for his contribution and leadership role in embracing innovation in healthcare.